Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

NOVOCURE LIMITED

(NVCR)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-06 pm EST
91.89 USD   -2.47%
01/19NovoCure Appoints Chief Commercial Officer Pritesh Shah as Chief Growth Officer
MT
01/19Novocure Announces Organizational Changes to Prepare for Future Growth
BU
01/19Novocure Announces Executive Changes
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Wells Fargo Upgrades NovoCure to Overweight From Equalweight, Adjusts Price Target to $89 From $74

11/29/2022 | 07:33am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
NOVOCURE LIMITED -2.47% 91.89 Delayed Quote.25.28%
WELLS FARGO & COMPANY 0.21% 47.68 Delayed Quote.15.48%
All news about NOVOCURE LIMITED
01/19NovoCure Appoints Chief Commercial Officer Pritesh Shah as Chief Growth Officer
MT
01/19Novocure Announces Organizational Changes to Prepare for Future Growth
BU
01/19Novocure Announces Executive Changes
CI
01/17Piper Sandler Adjusts NovoCure's Price Target to $80 From $70, Maintains Neutral Rating
MT
01/10Transcript : NovoCure Limited Presents at 41st Annual J.P. Morgan Healthcare ..
CI
01/10Insider Sell: NovoCure
MT
01/10Insider Sell: NovoCure
MT
01/09NovoCure Reports Lower Q4, Higher 2022 Preliminary Revenue
MT
01/09NovoCure Reports Lower Q4, Higher 2022 Preliminary Revenue
MT
01/09Novocure : The LUNAR study met its primary endpoint, demonstrating a statistically signifi..
PU
More news
Analyst Recommendations on NOVOCURE LIMITED
More recommendations
Financials (USD)
Sales 2022 537 M - -
Net income 2022 -85,6 M - -
Net Debt 2022 325 M - -
P/E ratio 2022 -114x
Yield 2022 -
Capitalization 9 644 M 9 644 M -
EV / Sales 2022 18,6x
EV / Sales 2023 18,2x
Nbr of Employees 1 167
Free-Float 98,9%
Chart NOVOCURE LIMITED
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 91,89 $
Average target price 103,75 $
Spread / Average Target 12,9%
EPS Revisions
Managers and Directors
Asaf Danziger Chief Executive Officer & Director
Ashley Cordova Chief Financial Officer
William F. Doyle Executive Chairman
Piet Hinoul Senior Vice President & Head-Medical
Moshe Giladi Chief Science Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVOCURE LIMITED25.28%9 644
PENUMBRA, INC.16.74%9 913
MASIMO CORPORATION14.53%8 907
SHOCKWAVE MEDICAL, INC.-8.90%6 770
GETINGE AB15.81%6 493
ASAHI INTECC CO., LTD.5.22%4 724